Sara Sadownik

Prevea Health

Papers

1

Total Citations

127

H-Index

1

About

Sara Sadownik is a leading health economist whose research focuses on the comparative effectiveness and cost-utility of treatments for clinically localised prostate cancer. Her most-cited work, a 2012 study published in *BJU International*, stands as the most comprehensive lifetime cost-utility analysis comparing primary treatments for this condition. With 127 citations, this landmark paper provided crucial evidence on the relative value of surgery, radiation, and active surveillance, directly addressing a critical gap in the literature where few high-quality studies had compared both effectiveness and costs. Sadownik’s contributions have helped shape clinical decision-making by demonstrating how different treatment pathways impact both patient outcomes and healthcare expenditures over a patient’s lifetime. Her rigorous modeling and patient-centered approach offer invaluable insights for clinicians, policymakers, and patients navigating the complex trade-offs in prostate cancer care. Through her work, Sadownik has established herself as a key voice in evidence-based health technology assessment, ensuring that cost-effectiveness data informs real-world treatment choices for one of the most common cancers in men.

Research Focus

Key Achievements

1
H-Index
1
Papers
127
Total Citations
127
Avg Citations/Paper
🏆 Most Cited Paper
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost‐utility analysis
127 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Prevea Health

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago